Monitor for any definitive agreement on an acquisition or in-licensing transaction, which would be the primary catalyst for this stock. Absent a deal, the stock is likely to trade on cash runway and general biotech sentiment, no near-term operational catalyst exists.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $7.38entry
- T+1 · 3mo ago −0.27%α +0.20% · $7.36
- T+5 · 3mo ago +2.71%α +4.08% · $7.58
- T+20 · 2mo ago +0.95%α +2.94% · $7.45
- T+60 · 8d ago −12.33%α −9.28% · $6.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts, the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.
Key Financial Metrics
Key Facts
- GAAP net loss per share was $0.63 for Q2 2026, vs $3.24 in Q2 2025
- Cash, cash equivalents, restricted cash and marketable securities totaled $69.9M as of June 30, 2026
- Cash runway expected to fund operating plan beyond 2027
- R&D expenses fell to $0.3M in Q2 2026 from $6.7M in Q2 2025
- G&A expenses fell to $5.1M in Q2 2026 from $6.2M in Q2 2025
- No in-process R&D expenses in Q2 2026 vs $10.0M in Q2 2025
- Company is evaluating potential acquisitions, in-licensing and related opportunities
- No revenue reported; company is pre-revenue
Financial Impact
Net loss of $4.3M in Q2 2026 vs $21.4M in Q2 2025; cash burn of ~$6.4M in H1 2026
Risk Factors
- No pipeline assets or revenue-generating operations, company is a cash shell seeking a transaction
- Cash burn continues at ~$3-4M per quarter, reducing the acquisition currency over time
- No guarantee that a suitable acquisition or in-licensing opportunity will be identified or consummated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001789769-26-000055 |
| Document: til-20260813.htm | 0001789769-26-000055 |
| Document: 0001789769-26-000055-index-headers.html | 0001789769-26-000055 |
| Document: 0001789769-26-000055-index.html | 0001789769-26-000055 |
| Document: 0001789769-26-000055.txt | 0001789769-26-000055 |
| 8-K Data (Synthetic) | 0001789769-26-000055 |
Track record
8 reports on TIL
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry $6.22 Now $5.75 −7.56% settles Dec 15
- Aug 13, 202613w ago Press Release Neutral 4/10 No price data
- Aug 13, 202613w ago 8-K Neutral 4/10 Viewing Entry $7.38 to $7.45 Now $5.75 −22.09% ▲ +0.95% +2.94% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
- May 15, 202626w ago Press Release Neutral 4/10 Entry $8.07 to $7.92 Now $5.75 −28.75% ▼ −1.86% −3.98% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $8.13 to $8.12 Now $5.75 −29.27% ▼ −0.12% −5.08% vs SPY
- Apr 3, 202632w ago 8-K Neutral 4/10 Entry $8.46 to $7.84 Now $5.75 −32.03% ▼ −7.33% −16.31% vs SPY
- Mar 27, 202633w ago Press Release Mixed 5/10 Entry $7.79 to $8.13 Now $5.75 −26.19% ▲ +4.36% −8.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers